bpc-157 compounding restrictions fda Regulatory Alert: The Legal Status of in and Clinical Practice – Holt Law fda warning bpc-157 unapproved peptide
Description
DistlerOHighlandKBGahlemannMAzumaAFischerAMayesMDet al
TB-4 Substantial human trial data for full-length TB-4 (corneal-healing Phase 2/3 as RGN-259, plus cardiac and wound-repair programs), with clean Phase 1 safety
gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing
Both peptides are chemically compatible in the same syringe and do not degrade each other
